Skip to main content
Full access
Letters to the Editor
Published Online: 1 December 2018

The Influence of Unmeasured Confounding Effects in a Study of Antipsychotic Discontinuation in First-Episode Schizophrenia

To the Editor: In the August 2018 issue of the Journal, Tiihonen and colleagues (1) explored an important yet unresolved area concerning antipsychotic discontinuation in the treatment of first-episode schizophrenia. Because this was a nonexperimental study, the presence of systematic bias due to confounding variables was not surprising. The confounding effect of a significantly different frequency of clozapine use among users and discontinuers was apparent in one of the supplementary tables in the article. A chi-square analysis using a 2×2 contingency table would reveal values of 38.6, 25.6, 12.3, and 4.2, respectively, for comparisons between the four groups of users and discontinuers (i.e., <1 year, 1–<2 years, 2–<5 years, and ≥5 years). All of these values are significant at the level of p<0.05. The frequency of clozapine use was overrepresented in the users. Higher consumption of clozapine might be a proxy for higher severity or greater treatment resistance. Both of these variables could potentially confound the results. This would be an example of confounding by indication, in which the indication (treatment resistance) or severity is related to both the exposure (antipsychotic use) and the outcome (relapse or rehospitalization). The second measured but unaccounted for confounding effect stemmed from the inclusion of subjects with schizoaffective disorder. Compared with schizophrenia, schizoaffective disorder may have better outcomes (2). The authors could have mentioned and compared the number and distribution of subjects with schizoaffective disorder among the users and discontinuers to examine the effect of this potential confounder.
Another likely confounding effect that is known to influence the risk of relapse in schizophrenia but was not measured in this study is history of substance abuse. A meta-analysis in patients with first-episode psychosis, consisting of 29 studies with at least 12 months of follow-up, showed that persistent substance use disorder increased the odds of relapse by threefold (3). The odds of relapse were lower than those due to treatment nonadherence but higher than all other potential predictors of relapse. We believe that information regarding substance use status was available and that the authors could have included the same. Other factors, such as poor premorbid adaptation to school and social withdrawal, could predict relapse, but these are difficult to measure through medical records (4). Nevertheless, the authors could have mentioned these in their discussion of limitations of the study.
One of the ways to estimate the effects of confounders is to calculate the variance in a multivariate regression analysis. The predictive value of even a highly significant covariate is judged to be low if the variance is small. In a Cox regression analysis, measurement of variance is difficult. In their article, Schemper and Henderson (5) proposed a model of estimating the predictive accuracy of covariates (risk factors) in a Cox proportional hazards model. There are other models as well (6). Had the authors of the present article used any of these models, the predictive accuracy of the risk factor (antipsychotic discontinuation) could have been measured. Influence of confounders could have been indirectly inferred from the predictive accuracy. In our opinion, in this kind of cohort study with a large number of unmeasured and unknown confounding effects, quoting only the hazard ratio (with confidence intervals) and the significance level is not enough.

References

1.
Tiihonen J, Tanskanen A, Taipale H: 20-year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia. Am J Psychiatry 2018; 175:765–773
2.
Harrow M, Grossman LS, Herbener ES, et al: Ten-year outcome: patients with schizoaffective disorders, schizophrenia, affective disorders and mood-incongruent psychotic symptoms. Br J Psychiatry 2000; 177:421–426
3.
Alvarez-Jimenez M, Priede A, Hetrick SE, et al: Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr Res 2012; 139:116–128
4.
Robinson D, Woerner MG, Alvir JM, et al: Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56:241–247
5.
Schemper M, Henderson R: Predictive accuracy and explained variation in Cox regression. Biometrics 2000; 56:249–255
6.
Heagerty PJ, Zheng Y: Survival model predictive accuracy and ROC curves. Biometrics 2005; 61:92–105

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 1266 - 1267
PubMed: 30501413

History

Accepted: 1 October 2018
Published online: 1 December 2018
Published in print: December 01, 2018

Keywords

  1. Schizophrenia
  2. Antipsychotics
  3. Outcome Studies
  4. Confounding Variables
  5. Predictive Accuracy
  6. Cox Regression

Authors

Details

Abhishek Ghosh, M.D., D.M. [email protected]
From the Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Dalton Noble, M.D.
From the Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Notes

Address correspondence to Dr. Ghosh ([email protected]).

Funding Information

The authors report no financial relationships with commercial interests.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share